IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e956005-1-e956005-17

  Foy, Kevin Chu ^a   Miller, Megan J ^a   Overholser, Jay ^a   Donnelly, Siobhan M ^b   Nahta, Rita ^b   Kaumaya, Pravin T P ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

antibodies; epitopes; immunogenicity; peptide mimics; resistance; vaccine candidates

Indexed keywords

CASPASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; PEPTIDE VACCINE; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CROSS REACTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MASS SPECTROMETRY; MOUSE; MTT ASSAY; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN PHOSPHORYLATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR VOLUME;

EID: 84938631417     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.956005     Document Type: Article

References (67)

1. S.Yakar, D.Leroith, P.Brodt. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev 2005; 16:407-20; PMID:15886048; http://dx.doi.org/10.1016/j.cytogfr.2005.01.010
2. M.N.Pollak, E.S.Schernhammer, S.E.Hankinson. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-18; PMID:15229476; http://dx.doi.org/10.1038/nrc1387
3. S.E.Hankinson, W.C.Willett, G.A.Colditz, D.J.Hunter, D.S.Michaud, B.Deroo, B.Rosner, F.E.Speizer, M.Pollak. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6; PMID:9593409; http://dx.doi.org/10.1016/S0140-6736(97)10384-1
4. U.Bergmann, H.Funatomi, M.Yokoyama, H.G.Beger, M.Korc. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55:2007-11; PMID:7743492
5. J.Ma, M.N.Pollak, E.Giovannucci, J.M.Chan, Y.Tao, C.H.Hennekens, M.J.Stampfer. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Nat Cancer Inst 1999; 91:620-5; PMID:10203281; http://dx.doi.org/10.1093/jnci/91.7.620
6. T.E.Adams, V.C.Epa, T.P.Garrett, C.W.Ward. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57:1050-93; PMID:10961344; http://dx.doi.org/10.1007/PL00000744
7. V.Papa, B.Gliozzo, G.M.Clark, W.L.McGuire, D.Moore, Y.Fujita-Yamaguchi, R.Vigneri, I.D.Goldfine, V.Pezzino. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53:3736-40; PMID:8339284
8. N.K.Taunk, S.Goyal, M.S.Moran, Q.Yang, R.Parikh, B.G.Haffty. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010; 96:204-8; PMID:20338651; http://dx.doi.org/10.1016/j.radonc.2010.03.009
9. J.L.Resnik, D.B.Reichart, K.Huey, N.J.Webster, B.L.Seely. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58:1159-64; PMID:9515800
10. J.H.Law, G.Habibi, K.Hu, H.Masoudi, M.Y.Wang, A.L.Stratford, E.Park, J.M.Gee, P.Finlay, H.E.Jones, Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68:10238-46; PMID:19074892; http://dx.doi.org/10.1158/0008-5472.CAN-08-2755
11. A.Hakam, Q.Fang, R.Karl, D.Coppola. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003; 48:1972-8; PMID:14627343; http://dx.doi.org/10.1023/A:1026122421369
12. J.W.Xu, T.X.Wang, L.You, L.F.Zheng, H.Shu, T.P.Zhang, Y.P.Zhao. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. PLoS One 2014; 9:e92847; PMID:24667580; http://dx.doi.org/10.1371/journal.pone.0092847
13. A.Ouban, P.Muraca, T.Yeatman, D.Coppola. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34:803-8; PMID:14506643; http://dx.doi.org/10.1016/S0046-8177(03)00291-0
14. Y.Lu, X.Zi, Y.Zhao, D.Mascarenhas, M.Pollak. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852-7; PMID:11752009; http://dx.doi.org/10.1093/jnci/93.24.1852
15. M.E.Balana, L.Labriola, M.Salatino, F.Movsichoff, G.Peters, E.H.Charreau, P.V.Elizalde. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 2001; 20:34-47; PMID:11244498; http://dx.doi.org/10.1038/sj.onc.1204050
16. A.Camirand, Y.Lu, M.Pollak. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002; 8:BR521-6; PMID:12503030
17. R.Nahta, L.X.Yuan, B.Zhang, R.Kobayashi, F.J.Esteva. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65:11118-28; PMID:16322262; http://dx.doi.org/10.1158/0008-5472.CAN-04-3841
18. R.Nahta. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemoth Res Pract 2012; 2012:648965; PMID:22830017; http://dx.doi.org/10.1155/2012/648965
19. Q.Jin, F.J.Esteva. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:485-98; PMID:19034632; http://dx.doi.org/10.1007/s10911-008-9107-3
20. R.Baserga, F.Peruzzi, K.Reiss. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107:873-7; PMID:14601044; http://dx.doi.org/10.1002/ijc.11487
21. B.Zahorowska, P.J.Crowe, J.L.Yang. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol 2009; 135:1137-48; PMID:19533170; http://dx.doi.org/10.1007/s00432-009-0622-4
22. A.K.Chakraborty, K.Liang, M.P.DiGiovanna. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008; 68:1538-45; PMID:18316619; http://dx.doi.org/10.1158/0008-5472.CAN-07-5935
23. C.Chen, Y.Zhang, Y.Zhang, J.Li, S.W.Tsao, M.Y.Zhang. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther 2014; 13:90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163.MCT-13-0558
24. P.Haluska, H.M.Shaw, G.N.Batzel, D.Yin, J.R.Molina, L.R.Molife, T.A.Yap, M.L.Roberts, A.Sharma, A.Gualberto, Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13:5834-40; PMID:17908976; http://dx.doi.org/10.1158/1078-0432.CCR-07-1118
25. D.D.Karp, L.G.Paz-Ares, S.Novello, P.Haluska, L.Garland, F.Cardenal, L.J.Blakely, P.D.Eisenberg, C.J.Langer, G.Blumenschein, Jr., Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27:2516-22; PMID:19380445; http://dx.doi.org/10.1200/JCO.2008.19.9331
26. M.L.Disis, E.Gad, D.R.Herendeen, V.P.Lai, K.H.Park, D.L.Cecil, M.M.O'Meara, P.M.Treuting, R.A.Lubet. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) 2013; 6:1273-82; PMID:24154719; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0182
27. K.C.Foy, M.J.Miller, N.Moldovan, W.E.Carson Iii, P.T.Kaumaya. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012; 1:1048-60; PMID:23170253; http://dx.doi.org/10.4161/onci.20708
28. K.C.Foy, M.J.Miller, N.Moldovan, T.Bozanovic, W.E.Carson Iii, P.T.Kaumaya. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology 2012; 1:1004-16; PMID:23170249; http://dx.doi.org/10.4161/onci.21057
29. K.C.Foy, Z.Liu, G.Phillips, M.Miller, P.T.Kaumaya. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 2011; 286:13626-37; PMID:21325276; http://dx.doi.org/10.1074/jbc.M110.216820
30. D.Vicari, K.C.Foy, E.M.Liotta, P.T.Kaumaya. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011; 286:13612-25; PMID:21321115; http://dx.doi.org/10.1074/jbc.M110.216812
31. J.Guevara-Aguirre, P.Balasubramanian, M.Guevara-Aguirre, M.Wei, F.Madia, C.W.Cheng, D.Hwang, A.Martin-Montalvo, J.Saavedra, S.Ingles, Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3:70ra13; PMID:21325617; http://dx.doi.org/10.1126/scitranslmed.3001845
32. K.C.Foy, R.M.Wygle, M.J.Miller, J.P.Overholser, T.Bekaii-Saab, P.T.Kaumaya. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol 2013; 191:217-27; PMID:23698748; http://dx.doi.org/10.4049/jimmunol.1300231
33. S.D.Allen, J.T.Garrett, S.V.Rawale, A.L.Jones, G.Phillips, G.Forni, J.C.Morris, R.G.Oshima, P.T.Kaumaya. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179:472-82; PMID:17579068; http://dx.doi.org/10.4049/jimmunol.179.1.472
34. J.T.Garrett, S.Rawale, S.D.Allen, G.Phillips, G.Forni, J.C.Morris, P.T.Kaumaya. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007; 178:7120-31; PMID:17513761; http://dx.doi.org/10.4049/jimmunol.178.11.7120
35. M.D.Lairmore, R.B.Lal, P.T.Kaumaya. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides. Biomed Peptides, Proteins Nucleic Acids: Struct, Syn Biol Act 1995; 1:117-22; PMID:9346842
36. T.P.Garrett, N.M.McKern, M.Lou, M.J.Frenkel, J.D.Bentley, G.O.Lovrecz, T.C.Elleman, L.J.Cosgrove, C.W.Ward. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 1998; 394:395-9; PMID:9690478; http://dx.doi.org/10.1038/28668
37. V.C.Epa, C.W.Ward. Model for the complex between the insulin-like growth factor I and its receptor: towards designing antagonists for the IGF-1 receptor. Protein Eng Des Sel 2006; 19:377-84; PMID:16772308; http://dx.doi.org/10.1093/protein/gzl022
38. P.T.Kaumaya, K.C.Foy, J.Garrett, S.V.Rawale, D.Vicari, J.M.Thurmond, T.Lamb, A.Mani, Y.Kane, C.R.Balint, Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009; 27:5270-7; PMID:19752336; http://dx.doi.org/10.1200/JCO.2009.22.3883
39. A.Jemal, R.Siegel, J.Xu, E.Ward. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073
40. T.Cartwright, D.A.Richards, K.A.Boehm. Cancer of the pancreas: are we making progress? A review of studies in the US oncology research network. Cancer Control 2008; 15:308-13; PMID:18813198
41. M.E.Valsecchi, M.McDonald, J.R.Brody, T.Hyslop, B.Freydin, C.J.Yeo, C.Solomides, S.C.Peiper, A.K.Witkiewicz. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 2012; 118:3484-93; PMID:22086503; http://dx.doi.org/10.1002/cncr.26661
42. M.Dong, Y.Nio, K.J.Guo, K.Tamura, Y.L.Tian, Y.T.Dong. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998; 18:4613-9; PMID:9891528
43. E.R.Sherwood, J.L.Van Dongen, C.G.Wood, S.Liao, J.M.Kozlowski, C.Lee. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998; 77:855-61; PMID:9528825; http://dx.doi.org/10.1038/bjc.1998.142
44. O.Stoeltzing, W.Liu, N.Reinmuth, F.Fan, A.A.Parikh, C.D.Bucana, D.B.Evans, G.L.Semenza, L.M.Ellis. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003; 163:1001-11; PMID:12937141; http://dx.doi.org/10.1016/S0002-9440(10)63460-8
45. T.Ishiwata, U.Bergmann, M.Kornmann, M.Lopez, H.G.Beger, M.Korc. Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas 1997; 15:367-73; PMID:9361090; http://dx.doi.org/10.1097/00006676-199711000-00006
46. P.Li, M.R.Veldwijk, Q.Zhang, Z.B.Li, W.C.Xu, S.Fu. Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells. BMC Cancer 2013; 13:297; PMID:23777562; http://dx.doi.org/10.1186/1471-2407-13-297
47. A.Inno, Di M.Salvatore, T.Cenci, M.Martini, A.Orlandi, A.Strippoli, A.M.Ferrara, C.Bagala, A.Cassano, L.M.Larocca, Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 2011; 10:325-32; PMID:21729677; http://dx.doi.org/10.1016/j.clcc.2011.03.028
48. Y.Lu, X.Zi, M.Pollak. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108:334-41; PMID:14648698; http://dx.doi.org/10.1002/ijc.11445
49. M.Tanner, A.I.Kapanen, T.Junttila, O.Raheem, S.Grenman, J.Elo, K.Elenius, J.Isola. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585-92; PMID:15634652
50. C.Chen, Y.Zhang, J.Li, S.W.Tsao, M.Y.Zhang. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther 2014; 13:90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163.MCT-13-0558
51. A.Esparis-Ogando, A.Ocana, R.Rodriguez-Barrueco, L.Ferreira, J.Borges, A.Pandiella. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 2008; 19:1860-9; PMID:18641009; http://dx.doi.org/10.1093/annonc/mdn406
52. A.Camirand, M.Zakikhani, F.Young, M.Pollak. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005; 7:R570-9; PMID:15987464; http://dx.doi.org/10.1186/bcr1028
53. N.Ioannou, A.M.Seddon, A.Dalgleish, D.Mackintosh, H.Modjtahedi. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 2013; 13:41; PMID:23367880; http://dx.doi.org/10.1186/1471-2407-13-41
54. N.K.Dakappagari, D.B.Douglas, P.L.Triozzi, V.C.Stevens, P.T.Kaumaya. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60:3782-9; PMID:10919651
55. N.K.Dakappagari, J.Pyles, R.Parihar, W.E.Carson, D.C.Young, P.T.Kaumaya. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003; 170:4242-53; http://dx.doi.org/10.4049/jimmunol.170.8.4242
56. N.K.Dakappagari, R.Sundaram, S.Rawale, A.Liner, D.R.Galloway, P.T.Kaumaya. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. J Pept Res 2005; 65:189-99; PMID:15705163; http://dx.doi.org/10.1111/j.1399-3011.2005.00212.x
57. N.K.Dakappagari, K.D.Lute, S.Rawale, J.T.Steele, S.D.Allen, G.Phillips, R.T.Reilly, P.T.Kaumaya. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 2005; 280:54-63; PMID:15507452; http://dx.doi.org/10.1074/jbc.M411020200
58. M.Srinivasan, R.M.Wardrop, I.E.Gienapp, S.S.Stuckman, C.C.Whitacre, P.T.Kaumaya. A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro. J Immunol 2001; 167:578-85; PMID:11418697; http://dx.doi.org/10.4049/jimmunol.167.1.578
59. M.Srinivasan, I.E.Gienapp, S.S.Stuckman, C.J.Rogers, S.D.Jewell, P.T.Kaumaya, C.C.Whitacre. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169:2180-8; http://dx.doi.org/10.4049/jimmunol.169.4.2180
60. S.D.Allen, S.V.Rawale, C.C.Whitacre, P.T.Kaumaya. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Peptide Res: Off J Am Peptide Soc 2005; 65:591-604; PMID:15885118; http://dx.doi.org/10.1111/j.1399-3011.2005.00256.x
61. D.Vicari, K.C.Foy, E.M.Liotta, P.T.Kaumaya. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011; 286:13612-25; PMID:21321115; http://dx.doi.org/10.1074/jbc.M110.216812
62. K.C.Foy, Z.Liu, G.Phillips, M.Miller, P.T.Kaumaya. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 2011; 286:13626-37; PMID:21325276; http://dx.doi.org/10.1074/jbc.M110.216820
63. K.C.Foy, M.J.Miller, N.Moldovan, W.E.Carson, P.T.P.Kaumaya. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1(7):1048-1060; doi: 10.4161/onci.20708
64. P.T.Kaumaya. Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure? Future Oncol 2011; 7:807-10; PMID:21732751; http://dx.doi.org/10.2217/fon.11.60
65. P.T.Kaumaya, K.C.Foy. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol 2012; 8:961-87; PMID:22894670; http://dx.doi.org/10.2217/fon.12.95
66. K.C.Foy, R.M.Wygle, M.J.Miller, J.P.Overholser, T.Bekaii-Saab, P.T.Kaumaya. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol 2013; 191:217-27; PMID:23698748; http://dx.doi.org/10.4049/jimmunol.1300231
67. K.Koninki, M.Barok, M.Tanner, S.Staff, J.Pitkanen, P.Hemmila, J.Ilvesaro, J.Isola. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 2010; 294:211-9; PMID:20193978; http://dx.doi.org/10.1016/j.canlet.2010.02.002